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Lymphoma of the mucosa-associated lymphoid tissue (MALT)
was introduced by Isaacson and Wright in the early 1980s as a
distinct clinicopathologic entity with characteristic histologic
features (Isaacson and Wright, 1983), and has been incorporated
into the REAL-classification under the term ‘extranodal marginal
zone B-cell lymphoma of MALT-type’ (Harris et al, 1994). MALT-
type lymphomas usually arise in the background of chronic anti-
genic stimulation triggered by persistent infections and/or
autoimmune processes (Greiner et al, 1994). The majority of these
tumours occur in the stomach, but this type of lymphoma may
affect virtually every organ in the human body, including the intes-
tine, salivary glands, thyroid, lung and ocular adnexa, but also,
though less frequently, the skin, urinary bladder and the gonads
(Isaacson and Norton 1994; Zucca et al, 1997). Accordingly, thor-
ough staging of patients before initiation of therapy is mandatory
once MALT-type lymphoma has been diagnosed, and prethera-
peutic work-up should include ophthalmologic examination,
otorhinolaryngologic investigation including sonography of the
salivary glands or magnetic resonance imaging if indicated,
gastroscopy with multiple biopsies, endosonography of the upper
GI tract, enteroclysis, colonoscopy, computed tomography (CT) of
thorax and abdomen and a bone marrow biopsy. With this staging
routine, a relatively high rate of multiorgan involvement could
recently be demonstrated in an unselected group of patients with
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Summary The majority of lymphomas of the mucosa-associated lymphoid tissue (MALT)-type arise in the stomach, but extragastric locations
are also frequently encountered. Due to previous results indicating that somatostatin receptor (SSTR)-expression distinguishes between
gastric and extragastric MALT-type lymphoma, we have initiated a study to evaluate the role of SSTR-scintigraphy for staging and follow-up
of patients with extragastric manifestations of MALT-type lymphoma. A total of 30 consecutive patients, including 24 with primary extragastric
MALT-type lymphoma, 5 patients with dissemination to extragastric sites (including colon, lung, parotid, ocular adnexa and breast) following
an initial gastric MALT-lymphoma and one patient with spread to stomach, lung and lymph nodes following parotid lymphoma were
prospectively studied. All patients had histologically verified MALT-type lymphoma: 2 patients had lymphoma presenting in the lung, 9 in the
ocular adnexa, 7 had lymphomas in the parotid, 2 patients had disease located in the breast, 3 patients had lymph-node relapse following
MALT-type lymphoma of the parotid, the lacrimal gland and the thyroid, and 1 had primary MALT-lymphoma of the liver. All patients underwent
SSTR-scintigraphy using 111In-DTPA-D-Phe1-Octreotide (111In-OCT) before initiation of therapy, while 13 also had a second scan after
treatment. The results of gamma camera imaging were compared to conventional staging. No positive scans could be obtained in patients
with dissemination following gastric lymphoma, while all patients with primary extragastric lymphoma had positive scans at the site of
histologically documented involvement before initiation of therapy. In addition, also the patient with secondary spread to stomach, lung and
lymph nodes was positive in all documented lymphoma sites. In one patient, focal tracer uptake in projection to the maxillary sinus was
documented, which was bioptically verified as inflammation. In the scans performed after therapy, focal tracer accumulation in the left orbit
indicated persistance of disease following irradiation in one patient with otherwise negative work-up, which was verified by MRI and biopsy
6 months later. In another patient, a positive scan indicated disease relapse in the lacrimal gland 9 months before clinical verification by
means of ultrasound. In one patient, a focus not present in the pretherapeutic scan was found in the ethmoidal sinus, corresponding to a
hyperplastic polyp. Both SST-scan as well as CT indicated disease persistance in one case, while negative scans corresponding to complete
remission as judged by conventional staging were obtained following therapy in the remaining patients, and absence of relapse has been
confirmed for a median follow-up of 2 years. These results indicate that 111In-OCT is an excellent tool for staging and non-invasive therapy-
monitoring in extragastric MALT-type lymphomas. These data further confirm our initial finding that gastric MALT-type lymphomas do not
express relevant amounts of respective SSTR, and that SSTR-scanning is able to distinguish between gastric vs extragastric origin of MALT-
type lymphoma irrespective of the site of presentation. © 2001 Cancer Research Campaign http://www.bjcancer.com
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MALT-type lymphoma of different localizations (Raderer et al,
2000). 
According to the finding that malignant lymphomas express
receptors (R) for somatostatin (SST), pilot studies using SST
analogues as therapeutic agents have been performed (Witzig et al,
1995), and radiolabelled octreotide (OCT), a long-acting SST
analogue preferentially binding to SSTR-subtypes 2 and 5, has
been used for imaging of such tumours (Goldsmith et al, 1995;
Leners et al, 1996; van-den-Anker Lugdenburg et al, 1996),
allowing for estimation of the tumour burden after a single tracer
injection. In a pilot series performed at our institution (Raderer et al,
1999) using 111In-DTPA-D-Phe1-OCT (111In-OCT, OCtreoScan®,
Mallinckrodt Medical, St Louis, USA), we could demonstrate a
difference in terms of SSTR-expression in gastric versus extragas-
tric MALT-type lymphomas. While no positive scans were
obtained in patients with gastric MALT-type lymphomas irrespec-
tive of size and stage of the disease, excellent visualization of
lymphomas originating in extragastric sites could be achieved
using  111In-OCT. Additional in vitro investigations by means of
Northern blotting disclosed expression of mRNA for SSTR2 in
tissue samples from 2 patients with extragastric lymphoma, while
this SSTR was absent from gastric lymphoma specimens (Raderer
et al, 1999). 
In view of these findings, we have initiated a follow-up study to
investigate prospectively the clinical potential of SSTR scintig-
raphy using 111In-OCT for staging and follow-up of patients with
extragastric MALT-type lymphoma. In addition, we have also
included patients with relapse in or spread to an extragastric site
following gastric MALT-type lymphoma to further test the thesis
that the site of origin is predictive of in-vivo expression of SSTR
with binding affinity for 111In-OCT. 
PATIENTS AND METHODS 
Patients 
Patients with a histologically verified diagnosis of MALT-type
lymphoma presenting in an extragastric site as assessed by a refer-
ence pathologist (AC) were eligible for this prospective study.
Histologic diagnosis of extranodal marginal zone B-cell lymphoma
of MALT-type was performed according to the criteria outlined by
Isaacson (Isaacson and Wright, 1983) and adopted in the REAL clas-
sification (Harris et al, 1994). In addition, immunologic phenotyping
on paraffin sections was done for demonstration of light-chain
restriction and the phenotype CD20+CD5–CD10-cyclinD1- which,
in context with the microscopic appearance, is consistent with low-
grade B-cell lymphoma of MALT-type (Harris et al, 1994). 
All patients underwent uniform staging procedures before
SSTR scintigraphy, consisting of ophthalmologic examination,
otorhinolaryngologic investigation including sonography of the
salivary glands or magnetic resonance imaging if indicated,
gastroscopy with multiple biopsies, endosonography of the upper
GI tract, enteroclysis, colonoscopy and bone marrow biopsy. All
lesions rated suggestive for the presence of lymphoma were
subjected to biopsy, and histologic samples obtained were evalu-
ated by a single individual (AC). 
Somatostatin receptor scintigraphy 
Somatostatin-receptor scanning was performed using commer-
cially available 111In-DTPA-D-Phe1-Octreotide (OctreoScan®,
Mallinckrodt Medical, St. Louis) 10 µ g DTPA-D-Phe1-OCT were
labelled with 120–150 MBq  111InCl3, according to the manufac-
turer’s description, and given by intravenous bolus injection. 
For planar and single photon emission tomography (SPET)
studies, a large field-of-view gamma camera (Toshiba, Japan)
equipped with a medium-energy general-purpose collimator was
used. At the time of injection, the field of view covered the
abdomen and some of the thorax. For recording and visualization,
standard techniques were applied. Sequential images were
recorded every minute, starting immediately after the injection for
30 minutes (matrix 128 × 128 pixels). Planar images in anterior,
posterior and lateral views were acquired at 30 minutes, between 3
and 6 hours, between 18 and 24 hours and at approximately 72
hours after intravenous injection covering brain/neck, thorax and
abdomen (matrix 128 × 128 pixels, 150–300 kcounts, scanning
time 10–20 min). SPET acquisition was performed in all patients
between 18 and 24 hours after injection. Both energy peaks were
used for scanning (set at 173 keV and 247 keV) with a 20%
window. SPET imaging was done in a 360˚ circle, using 6˚ steps,
30 seconds per step. After processing by a dedicated computer
(prefiltering with a Wiener filter, postfiltering with a ramp filter),
the data were reconstructed in 3 planes (slice thickness of 7 mm).
A yes-or-no system was used to evaluate the presence of neoplastic
lesions as judged both by planar and SPET-reconstructions. 
RESULTS 
A total of 30 consecutive patients with a diagnosis of MALT-type
lymphoma a priori presenting in an extragastric site (none of
whom had been included in our previously published series) were
studied prospectively (Table 1). 
In one patient with disease presentation in the lung, a history of
previous gastric MALT-type lymphoma could be established,
while staging work-up disclosed secondary involvement of the
parotid, the colon, the lacrimal gland and the breast in an addi-
tional 4 patients with gastric MALT-type lymphoma. In all 4
patients, HP-associated gastric MALT-type lymphoma had been
diagnosed between 9–14 months prior. In 24 patients, no evidence
of gastric involvement could be documented: 2 patients presented
with lymphoma located in the lung, 9 had lymphoma of the ocular
adnexa, 7 had lymphoma in the parotid, 2 patients had disease
located in the breast, 3 patients had lymph-node relapse (2
following resection of a MALT-type lymphoma of the thyroid and
the parotid, respectively, and one following potentially curative
radiation of a lacrimal lymphoma) and one patient had primary
lymphoma of the liver. 
In addition, also a patient with secondary spread to the stomach,
lung and hilar lymph nodes 3 years after radiation of a parotid
MALT-lymphoma was included in the series. Multiorgan disease
was found in a further 8 patients, including 5 patients with
lymphoma of the ocular adnexa with concomitant spread to the
pharynx, parotid, lung and breast and bilateral lacrimal lymphoma,
while 3 patients had bilateral parotid lymphoma. 
All patients underwent scintigraphy with 111In-OCT before initi-
ation of radiation or chemotherapy, while 13 patients were imaged
repeatedly during and/or after completion of therapy. Excellent
correlation with conventional imaging results was found for
pretherapeutic scans, as all sites of radiologically and histologi-
cally verified lymphomatous involvement could be imaged by
means of 111In-OCT. In terms of imaging time, it was found that the
early images did not improve the diagnostic capability of thetracer, and the best results were seen on images obtained 24–48
hours after injection of the tracer. While the tracer is avidly taken
up by the spleen, as has repeatedly been published, physiological
background due to hepatic or intestinal activity was not a problem
in our series, as also lesions within the liver as well as intra-
abdominal lymph nodes could be visualized. 
In one patient with bilateral parotid lymphoma visualized by
means of 111In-OCT, additional focal tracer uptake in projection to
the right maxillary sinus was seen, where the patient had been
operated due to chronic sinusitis 6 months prior. Panendoscopy
with multiple biopsies revealed the presence of an inflammatory
process, but no evidence of lymphoma. 
13 patients underwent a second injection of the tracer after
completion of therapy, while one patient with MALT-type
lymphoma of the liver was scanned after 2 cycles of chemotherapy
with 2-CdA and again after 4 cycles of treatment. In this patient,
only a slight change in appearance of the liver manifestations was
noted on CT-scanning after 2 cycles of therapy, while 111In-OCT
showed markedly decreased tracer uptake, indicating response to
chemotherapy. After completion of chemotherapy consisting of 4
cycles of 2-CdA, disappearance of 2 out of 4 initially demon-
strated lesions was found on CT and MRI, while scintigraphy still
demonstrated tracer uptake in all sites, albeit at reduced intensity,
rated suggestive of persistance of lymphoma. The patient under-
went surgery with removal of the liver segments initially involved,
and histologic work-up disclosed the presence of post-therapeutic
fibrosis along with multiple persisting foci of viable lymphoma
corresponding to 111In-OCT scintigraphy. 4 months after surgery,
MRI imaging and 111In-OCT scintigraphy were again performed,
showing no indication of persistent lymphoma. 
Post-therapeutic scan results showed good correlation with
conventional radiologic staging as judged after a median follow up
time of 24 months (range; 9–34 months), indicating complete
remission following treatment in 7 patients and persistence of
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Table 1 Patient characteristics 
Scan result
Sex/Age Localisation Before After therapy Therapy 
1. F/76 Lung pos n.d. Resection 
2. M/63 Conjunctiva pos neg Radiation 
3. F/83 Conjunctiva pos n.d. Radiation 
4. F/78 Cervical LNNc pos n.d. Cyclophosphamide 
5. M/59 Lunga neg n.d. CHOPc
6. F/49 Breast pos n.d. Resection 
7. M/36 Lung pos n.d. Resection, CHOP 
8. M/76 Lacrimal (bilateral) pos neg 2CdAd
9. M/70 Stomach neg n.d. Cyclophosphamide 
Colon neg n.d.
10. F/69 Parotid (bilateral) pos neg Radiation 
11. M/86 Lacrimal pos pos 2CdA 
Lung pos neg
12. M/69 Stomach neg n.d. 2CdA 
Lung neg n.d.
13. F/37 Parotid pos n.d. Radiation 
Lacrimal pos n.d. Radiation 
14. F/51 Parotid pos neg Resection 
15. F/64 Lacrimal pos pos Radiation 
16. F/61 Stomach neg n.d. Cyclophosphamide 
Lacrimal neg n.d.
17. M/32 Parotid (bilateral) pos pos 2CdA 
18. F/71 Parotid pos neg Radiation 
19. F/77 Lacrimal pos n.d. Radiation 
20. F/74 Abdominal LNNb pos pos 2CdA 
21. M/38 Parotid pos neg Radiation 
22. F/55 Breast pos n.d. Resection, radiation 
23. F/72 Lacrimal pos neg Radiation 
24. M/63 Lacrimal pos n.d. Radiation 
25. F/67 Stomach neg n.d. 2CdA 
Parotid neg n.d.
26. F/59 Liver pos pos 2CdA 
neg → resection 
27. M/74 Stomach neg n.d. CHOP 
Breast neg n.d.
28. M/46 Parotid pos n.d. Radiation 
29. F/69 Abdominal LNNf pos n.d. Radiation 
30. F/76 Stomachg pos n.d. CD-20 antibody 
Hilar lymph nodesg
Lungg
aresection of gastric primary, relapse within the lung 6 years later, btwo years after irradiation of a lacrimal MALT-
lymphoma, crelapse following two years after resection of a parotid MALT-lymphoma, dCHOP =
Cyclophosphamide, doxorubicin, vincrstine, prednisone, e2CdA = 2-chlorodeoxyadenosine, ffive years after
resection of a thyroid MALT-lymphoma, gthree years after successful irradiation of a parotid lymphoma. Somatostatin receptor scanning for extraintestinal MALT-lymphoma 1465
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disease in 2 patients. In 3 patients, however, conflicting results
were found. In 2 patients with lymphoma of the lacrimal gland,
persistent tracer uptake was seen after radiation and chemotherapy
(Figure 1) in one patient each, while both ultrasound and magnetic
resonance imaging indicated complete remission of the lymphoma.
During follow-up, relapse of the disease at the site of tracer accu-
mulation was subsequently seen also on MRI and ultrasound 6 and
9 months later, and both relapses were verified by means of biopsy
and histologic work-up. In the third patient, who suffered from
bilateral parotid lymphoma, decreased uptake of 111In-OCT corre-
sponded to partial remission after 4 cycles of chemotherapy as also
documented on MRI with subsequent biopsy, but an additional hot
spot not present in the pretherapeutic scan was found in projection
to the ethmoidal sinus. The correlating MRI image showed the
presence of a polypomatous lesion, which was removed in toto and
found to be hyperplastic. 
In the patient with secondary spread to the stomach, the lung
and hilar lymph nodes, focal tracer uptake could be demonstrated,
including the site of gastric relapse. As opposed to the excellent
scan results obtained in patients with extragastric MALT-type
lymphoma, none of the histologically verified lesions could be
visualized in the patients with a history of prior gastric lymphoma,
irrespective of size or localization. 
DISCUSSION 
MALT-type lymphoma is a relatively rare disease, but nevertheless
represents the third most common type of lymphoma accounting
for about 7% of all non-Hodgkin’s lymphomas (Pileri et al, 1998).
Both gastric as well as extragastric MALT lymphomas are rela-
tively indolent diseases, which are thought to remain localized for
a prolonged period of time. Recent studies, however, have shown
that roughly one third of MALT-type lymphomas are disseminated
upon diagnosis (Raderer et al, 2000; Thieblemont et al, 2000),
with patients suffering from primary extragastric lymphoma being
at higher risk for multiorgan involvement (Raderer et al, 2000). In
view of this, an exact diagnostic work-up is necessary in order to
identify patients suitable for local therapy such as radiation, and
diagnostic procedures should be quite extensive according to the
pronounced homing tendency of lymphocytes originating from
MALT. Thus, methods with the potential to facilitate staging are
welcome and warrant clinical evaluation in such patients. 
To date, scintigraphic methods have not widely been tested in
patients suffering from extranodal B-cell lymphomas of MALT-
type. Application of 18F-fluoro-deoxy-glucose positron emission
tomography (18F-FDG-PET) has been used for imaging and
assessment of viability in various types of lymphoma including
Hodgkin’s disease. A series performed at our institution, however,
has shown that 18F-FDG is not able to visualize sites involved
with MALT-type lymphoma, which is probably due to the low
proliferative activity of the lymphoma cells (Hoffmann et al,
1999). Recently, we have reported different expression of SSTR in
extranodal lymphomas of MALT-type with regard to the origin of
the neoplasia. In our pilot study, only patients with primary extra-
gastric MALT lymphomas were found to have positive scans using
the radiolabelled SST analogue 111In-OCT, while visualization of
the tumours was not possible in patients with primary gastric
MALT-type lymphomas (Raderer et al, 1999). According to these
findings in a relatively limited series of patients, we have
performed a consecutive study to evaluate the impact of SSTR
scintigraphy on staging and follow-up of patients with extragastric
MALT lymphoma. 
The results of this study demonstrate that SSTR-receptor
scintigraphy is a valuable tool for staging and follow-up of such
patients. Positive scan results were obtained at the sites of radiolog-
ically and histologically ascertained tumoural involvement in all
patients with primary extragastric MALT lymphoma. In addition
to the excellent accuracy for pretherapeutic staging, non-invasive
assessment of therapeutic efficacy was possible in the 13 patients
undergoing repeated scanning with 111In-OCT as judged by a
median follow-up period of 24 months (range, 9–34 months). 2
patients, who showed persistence of tracer uptake despite normal
conventional work-up following treatment were diagnosed with
clinically manifest relapse 6 and 9 months after the respective
scintigraphy, and 111In-OCT was more accurate in determining
post-therapeutic residual lymphoma than conventional imaging
including CT and MRI in another patient with MALT-type
lymphoma of the liver. 
In contrast, none of the patients with a negative scintigraphy
after therapy has relapsed during the follow-up period in spite of
discordant CT results in 2 patients. In these patients, persistent or
relapsing lymphoma was suggested on CT scan of the thorax,
while no corresponding focal tracer uptake was seen on SSTR
scanning. In both patients, persistence of lymphoma was ruled out
by unchanged CT over a period of 8 and 14 months, respectively,
while fine needle biopsy without evidence of lymphoma was
performed in one patient. 
In order to further test our hypothesis that gastric MALT
lymphomas do not express relevant amounts of SSTR, we have
also included 5 patients with extragastric relapse or consecutive
dissemination following diagnosis of gastric MALT-lymphoma. In
keeping with our initial results, no tracer uptake indicating
neoplastic involvement could be seen in these patients. This finding
adds further support to the notion that SSTR expression is depen-
dent on the origin of the lymphoma rather than the localization of
the lesion. However, a note of caution has to be added, as evalua-
tion of SSTR expression on the cellular level has only been
performed in a small pilot series by means of Northern blotting
(Raderer et al, 1999) on fresh tumour samples both from gastric as
Figure 1 Planar imaging depicting mediastinal and hilar lymph node
relapse following successful irradiation of a parotid MALT-type lymphoma,
indicated by multiple hot-spots within the thorax 1466 M Raderer et al 
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well as extragastric origin. While the results obtained also indi-
cated a difference in expression of SSTR subtypes, large-scale
studies with paraffin-embedded material have not been performed,
as there are no commercially available antibodies targetting SSTR
subtypes 1–5 suitable for this application. While our data are
highly suggestive that there is indeed a difference in terms of
SSTR expression on the cellular level, definite proof by immuno-
histochemistry is still lacking. 
Taken together, our data indicate that SSTR scintigraphy using
111In-OCT is an excellent tool for staging and follow-up in patients
suffering from primary extragastric MALT-type lymphoma, allowing
for non-invasive evaluation of treatment efficacy, which appears to
be superior when compared to conventional imaging techniques. In
addition,  111In-OCT scintigraphy appears to allow distinction
between gastric versus extragastric origin of the MALT-type
lymphoma in patients presenting with lesions located outside the GI
tract. In addition, 111In-OCT scanning might identify patients suitable
for therapy with labelled or unlabelled SST analogues. 
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